Last reviewed · How we verify

Miconazole Nitrate 2%

Aesculape CRO Belgium BV · FDA-approved active Small molecule

Miconazole nitrate disrupts fungal cell membrane integrity by inhibiting ergosterol synthesis, leading to cell death.

Miconazole nitrate disrupts fungal cell membrane integrity by inhibiting ergosterol synthesis, leading to cell death. Used for Topical fungal infections including tinea pedis, tinea corporis, tinea cruris, and candidiasis, Pityriasis versicolor.

At a glance

Generic nameMiconazole Nitrate 2%
SponsorAesculape CRO Belgium BV
Drug classImidazole antifungal
TargetLanosterol 14α-demethylase (CYP51)
ModalitySmall molecule
Therapeutic areaDermatology / Infectious Disease
PhaseFDA-approved

Mechanism of action

Miconazole is an imidazole antifungal that inhibits the fungal cytochrome P450 enzyme lanosterol 14α-demethylase, blocking the conversion of lanosterol to ergosterol. This disrupts the fungal cell membrane structure and permeability, ultimately causing fungal cell death. It is effective against a broad spectrum of dermatophytes, yeasts, and other fungi.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: